Cipla
Cipla Limited (stylized as Cipla) is an Indian multinational pharmaceutical company, headquartered in Mumbai. Cipla primarily develops medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and other medical conditions.
| Cipla | |
| Formerly | Chemical Industrial & Pharmaceutical Laboratories Ltd. (1935–1984) |
| Company type | Public |
| BSE: 500087 NSE: CIPLA NSE NIFTY 50 Constituent | |
| ISIN | INE059A01026 |
| Industry | Pharmaceuticals |
| Founded | 1935 |
| Founder | Khwaja Abdul Hamied |
| Headquarters | Mumbai, Maharashtra, India |
Area served | Worldwide |
Key people |
|
| Products | Pharmaceuticals and diagnostics |
| Revenue | ₹22,753 crore (US$2.8 billion) (FY23) |
| ₹5,027 crore (US$630 million) (FY23) | |
| ₹2,802 crore (US$350 million) (FY23) | |
| Total assets | ₹23,662.56 crore (US$3.0 billion) (2020) |
| Total equity | ₹15,763.00 crore (US$2.0 billion) (2020) |
Number of employees | 22,036 |
| Subsidiaries | Invagen Pharmaceuticals |
| Website | www.cipla.com |
Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third largest drug producer in India.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.